PDF factsheet
      Z

Capecitabine containing-regimen in advanced breast cancer (metastatic) for all type of patients, clinical trials results

capecitabine versus CMF
Oshaughnessy, 2001
intermittent oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period)
versus
intravenous CMF (cyclophosphamide. methotrexate, 5-fluorouracil [5-FU]) administered every three weeks
-line therapy for advanced/metastatic breast cancer
capecitabine versus control
Joensuu, 2009
NCT00114816
three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine
versus
three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil
women with axillary node-positive or high-risk node-negative breast cancer open-label
capecitabine versus cyclophosphamide, methotrexate, and 5-fluorouracil
Stockler, 2011

versus
capecitabine versus docetaxel + epirubicin
Mavroudis, 2010
docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles
versus
docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1
women with advanced breast cancer
capecitabine versus paclitaxel
Talbot, 2002
intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients))
versus
i.v. paclitaxel (175 mg m(-2),
patients with metastatic/advanced breast cancer pretreated with anthracyclines
Moiseenko, 2000

versus
capecitabine versus pegylated liposomal doxorubicin
J├Ąger, 2010

versus
capecitabine versus vinorelbine
EORTC 10001 (Pajk), 2008
capecitabine 1250 mg/m(2) orally bid days 1-14
versus
vinorelbine 30 mg/m(2) i.v. days 1 and 8, both given every 3 weeks
patients with anthracycline- and taxane-pretreated metastatic breast cancer
capecitabine docetaxel versus docetaxel
GeparQuattro, 2010
NCT00288002

versus
Patients with large operable or locally advanced tumors, with hormone receptor-negative tumors, or with receptor-positive tumors but also clinically node-positive disease
capecitabine MPA versus IV CT
Hori, 0
capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide
versus
5-fluorouracil + adriamycin + CPA) plus MPA
metastatic breast cancer
capecitabine + docetaxel versus docetaxel alone
Verma, 2005
21-day cycles of oral capecitabine 1250 mg/m2 twice daily, on Days 1-14, plus docetaxel 75 mg/m2 Day 1
versus
docetaxel 100 mg/m2 on Day 1
patients with anthracycline-pretreated metastatic breast carcinoma
Miles, 2004

versus
patients with anthracycline-pretreated advanced/metastatic breast cancer
O'Shaughnessy, 2002
21-day cycles of oral capecitabine 1,250 mg/m(2) twice daily on days 1 to 14 plus docetaxel 75 mg/m(2) on day 1
versus
docetaxel 100 mg/m(2) on day 1
patients with advanced breast cancer
capecitabine + docetaxel versus doxorubicin + cyclophosphamide
Lee, 2008

versus
women with axillary node positive, stage II/III breast cancer

  Options


in first

in second

  Filter